Disruption of the interactions between the subunits of herpesvirus DNA polymerases as a novel antiviral strategy  A. Loregian, G. Palù  Clinical Microbiology.

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Twelve years of dengue surveillance in Belgian travellers and significant increases in the number of cases in 2010 and 2013  J. Verschueren, L. Cnops,
Gut bacterial microbiota and obesity
Approach to diagnosis of infective endocarditis
S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler 
Herpes zoster in non-hospitalized children
Migrant health—a cause for concern?
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Gastroenteritis outbreak caused by norovirus associated with the children's club of a hotel located in Majorca, Spain  A. Doménech-Sánchez  Clinical Microbiology.
Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals  G. Ippolito  Clinical Microbiology and Infection 
J.-P. Van geertruyden  Clinical Microbiology and Infection 
Hepatitis B and C virus-related carcinogenesis
Infectious causes of cancer: an evolving educational saga
Virological tools to diagnose and monitor hepatitis C virus infection
G. Zhao, H. Zhai, Q. Yuan, S. Sun, T. Liu, L. Xie 
R. Cantón  Clinical Microbiology and Infection 
P. Nordmann, L. Poirel  Clinical Microbiology and Infection 
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Non-antibiotic strategies for sepsis
An eye-catching acanthocephalan
N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R
Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?  T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt 
Prevalence of Toscana virus antibodies in residents of Croatia
Clinical Microbiology and Infection
Surveillance of Legionnaires’ disease in Austria
Vector control: a cornerstone in the malaria elimination campaign
Training for the infectious diseases speciality in Norway
R. Karakus, K. Caglar, C. Aybay  Clinical Microbiology and Infection 
B. Gordts  Clinical Microbiology and Infection 
Laboratory diagnosis and biosafety issues of biological warfare agents
Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response.
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
Elements of design: the knowledge on which we build
Levofloxacin in the treatment of ventilator-associated pneumonia
G. Pappas  Clinical Microbiology and Infection 
Metagenomics and probiotics
Hepatitis B and C virus-related carcinogenesis
Laboratory diagnosis of Clostridium difficile disease
The practice of travel medicine in Europe
Sexually acquired Zika virus: a systematic review
Systematic review of antibiotic consumption in acute care hospitals
Update on antifungal resistance in Aspergillus and Candida
Abstracts cont. Clinical Microbiology and Infection
Pandemic lineages of extraintestinal pathogenic Escherichia coli
Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection  E. Knops, E. Heger  Clinical Microbiology.
Vaccinations against respiratory tract infections at Hajj
A.P. Underwood, J. Green  Clinical Microbiology and Infection 
Antimicrobial drug development – the past, the present, and the future
H. Leblebicioglu, C. Eroglu  Clinical Microbiology and Infection 
Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS  M. Rybicka,
Statin use and clinical outcomes among pneumonia patients
Clinical Microbiology and Infection
Clinical Microbiology and Infection
N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
The atypical pneumonias: clinical diagnosis and importance
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
Are we losing the fight against malaria one more time?
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Comparative study of pediculicidal effect of medical plants
CMI readers' survey Clinical Microbiology and Infection
Rajko Saletinger, Mario Poljak, Franc Strle 
The future of diagnostic bacteriology
Presentation transcript:

Disruption of the interactions between the subunits of herpesvirus DNA polymerases as a novel antiviral strategy  A. Loregian, G. Palù  Clinical Microbiology and Infection  Volume 11, Issue 6, Pages 437-446 (June 2005) DOI: 10.1111/j.1469-0691.2005.01149.x Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Disruption of the herpesvirus DNA polymerase complex. (a) The DNA polymerase of herpesviruses is composed of a catalytic subunit, which possesses basal activity, and an accessory protein. By interacting with the catalytic subunit, the accessory protein stimulates the processivity of the enzyme. In both the HSV-1 and the HCMV DNA polymerase, the region of the catalytic subunit responsible for binding to the accessory protein has been localised to the C-terminal region (here represented as a rectangle). (b) Peptides corresponding to the C-terminal region of the catalytic subunit or small molecules mimicking the side-chain of residues crucial for subunit interaction are capable of disrupting the DNA polymerase complex, thus inhibiting the processivity of the virus enzyme. Clinical Microbiology and Infection 2005 11, 437-446DOI: (10.1111/j.1469-0691.2005.01149.x) Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Inhibitory peptides or small molecules directed against subunit interactions of herpesvirus DNA polymerases. n.d., not determined. References: a[35]; b[34,36]; c[40]; d[52]. Clinical Microbiology and Infection 2005 11, 437-446DOI: (10.1111/j.1469-0691.2005.01149.x) Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions